Compare EQ & PRPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EQ | PRPL |
|---|---|---|
| Founded | 2017 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Home Furnishings |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.5M | 76.9M |
| IPO Year | 2018 | N/A |
| Metric | EQ | PRPL |
|---|---|---|
| Price | $1.53 | $0.68 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 1 |
| Target Price | $1.00 | $1.00 |
| AVG Volume (30 Days) | ★ 543.2K | 237.3K |
| Earning Date | 11-13-2025 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $4,392,000.00 | ★ $457,012,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.69 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.27 | $0.56 |
| 52 Week High | $2.35 | $1.26 |
| Indicator | EQ | PRPL |
|---|---|---|
| Relative Strength Index (RSI) | 63.38 | 37.08 |
| Support Level | $1.17 | $0.71 |
| Resistance Level | $1.32 | $0.75 |
| Average True Range (ATR) | 0.12 | 0.04 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 94.12 | 14.20 |
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.
Purple Innovation Inc is a comfort innovation company. The company designs, manufactures and sells a range of comfort technology offerings, including mattresses, a pillow, cushions, sheets, bed platforms and other products. The Company has one reportable segment that operates an omni-channel distribution which allows the Company to offer a seamless shopping experience to its customers across multiple sales channels. It sells its products through its direct-to-consumer e-commerce channels, retail brick-and-mortar wholesale partners, Purple showrooms, and third-party online retailers.